Literature DB >> 15986972

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature.

James Haan1, Thomas Scalea.   

Abstract

Management of acute bleeding in patients who are Jehovah's Witnesses remains a challenge. Clearly, the most important concept is meticulous and early hemostasis to minimize ongoing blood loss. This is generally followed by supportive measures. Dilutional coagulopathy can present a real challenge, as therapeutic options are quite limited in this group of patients. We present a patient who arrived in hemorrhagic shock, and despite early surgical therapy, his significant blood loss caused dilutional coagulopathy that we treated with activated factor VIIa. While use of factor VIIa after injury is gaining popularity, data on its use in patients who are Jehovah's Witnesses is quite limited. In this case, we believe the product was life-saving. Most importantly, there were no religious objections to its use. In appropriate patients, when surgical bleeding is controlled and there is still evidence of dilutional coagulopathy, factor VIIa may have a real role in patients, particularly those who are Jehovah's Witnesses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986972

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Cerebral oximetry monitoring during aortic arch aneurysm replacement surgery in Jehovah's Witness patient -A case report-.

Authors:  Seong-Hyop Kim; Tae-Gyoon Yoon; Tae-Yop Kim; Hae-Kyoung Kim; Woo-Sung Sung
Journal:  Korean J Anesthesiol       Date:  2010-02-28

2.  Optimizing Outcomes in the Jehovah's Witness Following Trauma: Special Management Concerns for a Unique Population.

Authors:  Chrysanthos Georgiou; Kenji Inaba; Joseph DuBose; Pedro G R Teixeira; Pantelis Hadjizacharia; Ali Salim; Carlos Brown; Peter Rhee; Demetrios Demetriades
Journal:  Eur J Trauma Emerg Surg       Date:  2009-07-09       Impact factor: 3.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.